FDA approves second monoclonal antibody treatment for early Alzheimer’s disease
By
Kristen Fischer
Jul 02, 2024
The US Food and Drug Administration (FDA) approved a second monoclonal antibody treatment for for early Alzheimer’s on Tuesday. Eli Lilly’s Kisunla (donanemab), which has proven to slow the disease...